Publication Date
| In 2025 | 0 |
| Since 2024 | 1 |
| Since 2021 (last 5 years) | 1 |
Descriptor
| Autism Spectrum Disorders | 1 |
| Drug Therapy | 1 |
| Foreign Countries | 1 |
| Intelligence | 1 |
| Outcomes of Treatment | 1 |
| Randomized Controlled Trials | 1 |
| Scores | 1 |
| Symptoms (Individual… | 1 |
| Young Children | 1 |
Source
| Journal of Autism and… | 1 |
Author
| Brian Cornblatt | 1 |
| Daomeng Cheng | 1 |
| Hua Jin | 1 |
| Jed W. Fahey | 1 |
| Jen Arriaza | 1 |
| Jianjun Ou | 1 |
| Jingjing Lin | 1 |
| Jingping Zhao | 1 |
| John M. Davis | 1 |
| Lian Huang | 1 |
| Renrong Wu | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
| China | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkJianjun Ou; Robert C. Smith; Russell H. Tobe; Jingjing Lin; Jen Arriaza; Jed W. Fahey; Ruiting Liu; Ying Zeng; Yanan Liu; Lian Huang; Yidong Shen; Yamin Li; Daomeng Cheng; Brian Cornblatt; John M. Davis; Jingping Zhao; Renrong Wu; Hua Jin – Journal of Autism and Developmental Disorders, 2024
Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated…
Descriptors: Drug Therapy, Outcomes of Treatment, Autism Spectrum Disorders, Randomized Controlled Trials
